Head to Head Review: Nanobiotix (NASDAQ:NBTX) and NRx Pharmaceuticals (NASDAQ:NRXP)

Nanobiotix (NASDAQ:NBTX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nanobiotix and NRx Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1	0	4	0	2.60
NRx Pharmaceuticals	1	1	4	0	2.50

Nanobiotix presently has a consensus target price of $25.00, suggesting a potential downside of 21.46%. NRx Pharmaceuticals has a consensus target price of $38.00, suggesting a potential upside of 1,420.00%. Given NRx Pharmaceuticals’ higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Nanobiotix.

Risk and Volatility

Nanobiotix has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Profitability

This table compares Nanobiotix and NRx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
NRx Pharmaceuticals	N/A	N/A	-265.03%

Valuation & Earnings

This table compares Nanobiotix and NRx Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87 million	41.79	-$27.11 million	N/A	N/A
NRx Pharmaceuticals	$1.23 million	67.22	-$28.62 million	($1.39)	-1.80

Nanobiotix has higher revenue and earnings than NRx Pharmaceuticals.

Insider and Institutional Ownership

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Nanobiotix beats NRx Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.